Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average PT from Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $20.00.

A number of research analysts have issued reports on ANRO shares. Stifel Nicolaus decreased their price target on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird cut their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Finally, Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd.

Institutional Investors Weigh In On Alto Neuroscience

Large investors have recently bought and sold shares of the company. Federated Hermes Inc. increased its position in shares of Alto Neuroscience by 33.3% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after purchasing an additional 3,000 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Alto Neuroscience by 619.2% during the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after buying an additional 3,715 shares in the last quarter. Philadelphia Financial Management of San Francisco LLC raised its position in shares of Alto Neuroscience by 1.5% in the third quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock valued at $5,147,000 after buying an additional 6,663 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of Alto Neuroscience in the second quarter worth about $113,000. Finally, Jane Street Group LLC acquired a new position in Alto Neuroscience during the third quarter worth about $124,000.

Alto Neuroscience Stock Performance

NYSE:ANRO opened at $4.31 on Monday. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $8.77 and its 200-day moving average price is $10.92. Alto Neuroscience has a 1-year low of $3.61 and a 1-year high of $24.00.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05. As a group, analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.